BCM
ANTH

Bridgeway Capital Management’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Bridgeway Capital Management’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-18,744
Closed -$463K – 1512
2016
Q2 		$463K Buy
+18,744
New +$530K 0.01% 1081

Other funds holding ANTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's ANTH Position: Q3 2016 in Review

Bridgeway Capital Management sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q3 2016, closing a stake of 18,744 shares — an estimated $463K sold.

Bridgeway Capital Management first reported a position in ANTH in Q2 2016 and held it in 1 quarter. The position peaked at $463K in Q2 2016. 72 funds tracked by Wall St. Rank hold ANTH as of Q3 2016.

  • Bridgeway Capital Management reported no remaining Anthera Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Bridgeway Capital Management sold 18,744 Anthera Pharmaceuticals, Inc. shares in Q3 2016, an estimated $463K.
  • Bridgeway Capital Management first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
  • Bridgeway Capital Management's Anthera Pharmaceuticals, Inc. position peaked at $463K in Q2 2016.
  • 72 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q3 2016.

Based on Bridgeway Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.